LENSAR (NASDAQ:LNSR) Posts Earnings Results, Misses Expectations By $0.28 EPS

LENSAR (NASDAQ:LNSR) issued its quarterly earnings results on Tuesday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.28), FiscalAI reports. The company had revenue of $14.13 million during the quarter, compared to the consensus estimate of $14.30 million. LENSAR had a negative return on equity of 529.08% and a net margin of 57.57%.

Here are the key takeaways from LENSAR’s conference call:

• Recurring revenue rose 17% to $12.6 million, procedure revenue increased 17%, and procedure volume grew 12% year over year. Recurring revenue made up 89% of total revenue, helping offset a 1% decline in total revenue as system sales fell against a strong prior-year comparison.
• LENSAR placed 10 ALLY systems, bringing its installed base to approximately 225, while market share edged up to 24.5%. The company said new robotic docking features are expected around the end of Q1 2027, potentially supporting further adoption.
• Gross margin improved to 58% from 42%, operating loss narrowed to about $1.4 million, and adjusted EBITDA turned positive at $1.7 million. GAAP net loss widened to $4.7 million, largely due to a non-cash warrant-liability expense.
• Management described overseas commercial activity as still recovering after distributor disruption, seasonal holidays, and reimbursement changes, and expects a gradual ramp into 2027. Executives also noted that U.S. cataract procedure volumes have recently been slightly softer.
• Cash and investments were $12.6 million at quarter-end, supplemented by a new $10 million revolving credit line. Management anticipates $1 million–$2 million of cash burn for the rest of 2026 and said it expects to move closer to break-even at some point in 2027.

LENSAR Stock Performance

Shares of NASDAQ:LNSR traded down $0.64 during trading on Tuesday, reaching $4.83. 114,054 shares of the stock traded hands, compared to its average volume of 90,033. The stock has a market cap of $59.30 million, a P/E ratio of -14.62 and a beta of 1.03. The stock has a 50-day moving average of $6.73 and a two-hundred day moving average of $7.32. LENSAR has a 52-week low of $4.62 and a 52-week high of $12.94.

Wall Street Analysts Forecast Growth

LNSR has been the subject of a number of analyst reports. Loop Capital set a $11.00 price objective on LENSAR in a research report on Monday, September 28th. Weiss Ratings raised LENSAR from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 22nd. BTIG Research cut their target price on LENSAR from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday. Lake Street Capital reissued a “buy” rating and issued a $13.00 target price on shares of LENSAR in a research note on Thursday, August 13th. Finally, Wall Street Zen downgraded LENSAR from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $11.00.

About LENSAR

LENSAR, Inc is a medical technology company focused on ophthalmic laser systems used in cataract surgery and other procedures involving the eye. The company develops and commercializes femtosecond laser technology designed to assist surgeons with key steps of cataract surgery, including corneal incisions, capsulotomy and lens fragmentation.

Its product portfolio includes the LENSAR Laser System, which incorporates image-guidance and planning technologies intended to support precise, customized procedures.